UK's NICE changes guidance to recommend Eli Lilly's Efient for blood clots

23 July 2014

The National Institute for Health and Care Excellence (NICE), the UK’s health care guidance body, has reviewed and updated its guidance on Efient (prasugrel), produced by US drug major Eli Lilly (NYSE: LLY).

The new guidance recommends the drug in combination with aspirin for preventing blood clots in people who have had a heart attack or who have unstable angina, also known as acute coronary syndromes, and who are also having a procedure to widen narrowed arteries in the heart.

Prasugrel is in the drug class known as anti-platelets, which reduce or prevent the formation of blood clots so that blood flow to the heart can be maintained and prevent further damage. Acute coronary syndromes are caused when a blood clot causes one of the large blood vessels that carry oxygen-rich blood to the heart to become narrowed or blocked. This reduces blood flow to the heart and the affected part can become permanently damaged.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK